Revolution Medicines officer plans $667K sale

Rule 144 notice reports planned and recent common stock sales by an officer of Revolution Medicines, Inc.

Available on EDGAR 09/15/2026 - 06:06 PM EDT Accepted by SEC EDGAR 09/15/2026 - 06:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) is the issuer for a Rule 144 notice filed on behalf of officer Jeff Cislini covering potential sales of company common stock. The notice lists 3,272 shares to be sold through E*TRADE Financial Corporation in connection with RSU vesting on September 15, 2026, for services rendered.

The filing also reports prior sales of company common stock by Jeff Cislini during the past three months, including 56,894 shares on August 21, 2026 and 2,157 shares on June 16, 2026.

Key Figures

Shares to be sold: 3,272 shares Aggregate market value of planned sale: $666,735.44 Shares sold August 21, 2026: 56,894 shares +4 more

7 metrics

Shares to be sold 3,272 shares Common stock covered by the Rule 144 notice tied to RSU vesting on September 15, 2026

Aggregate market value of planned sale $666,735.44 Value associated with 3,272 shares of common stock listed with E*TRADE Financial Corporation

Shares sold August 21, 2026 56,894 shares Common stock sold by Jeff Cislini during the past three months

Proceeds from August 21, 2026 sale $11,904,246.84 Value of 56,894 shares of common stock sold

Shares sold June 16, 2026 2,157 shares Additional common stock sale by Jeff Cislini during the past three months

Proceeds from June 16, 2026 sale $336,748.90 Value of 2,157 shares of common stock sold

Issuer contact phone 650-481-6801 Phone number listed for Revolution Medicines, Inc.

Key Terms

Rule 144, RSU vesting, services rendered

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU vesting financial

"Common Stock | 09/15/2026 | RSU vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

services rendered financial

"3272 | 09/15/2026 | Services rendered"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Revolution Medicines, Inc. (RVMD)?

The Form 144 notice discloses that an officer, Jeff Cislini, may sell 3,272 shares of Revolution Medicines common stock in connection with RSU vesting on September 15, 2026, and it lists related sales of common stock in the prior three months.

How many RVMD shares are covered by the planned sale in this Form 144?

The planned sale covers 3,272 shares of Revolution Medicines common stock. These shares are tied to RSU vesting on September 15, 2026 and are to be sold through E*TRADE Financial Corporation for services rendered.

What prior RVMD stock sales by Jeff Cislini are reported in the last three months?

The notice reports two prior sales of Revolution Medicines common stock: 56,894 shares sold on August 21, 2026 for proceeds of $11,904,246.84, and 2,157 shares sold on June 16, 2026 for proceeds of $336,748.90.

Who is the person for whose account RVMD securities are to be sold in this Form 144?

The securities are to be sold for the account of Jeff Cislini, identified as an officer of Revolution Medicines, Inc. The filing provides his name and indicates that the common stock sales relate to his holdings.

Which broker is listed for the potential RVMD stock sale in the Form 144?

The broker listed is E*TRADE Financial Corporation, located in Alpharetta, Georgia. The Form 144 associates E*TRADE with the planned sale of 3,272 shares of Revolution Medicines common stock.

What is the timing of the RSU-related RVMD share sale in this Form 144?

The Form 144 states that 3,272 shares of Revolution Medicines common stock are tied to RSU vesting on September 15, 2026. That date is listed as the event date for the securities to be sold and as the date of issuance for services rendered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001969082
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	650-481-6801
Name of Person for Whose Account the Securities are To Be Sold	Cislini Jeff
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	3272	666735.44	214336418	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/15/2026	RSU vesting	Issuer			3272	09/15/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	08/21/2026	56894	11904246.84
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2026	2157	336748.90

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/31/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jack Anders, as Attorney-in-fact for Jeff Cislini
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)